



Briefing Call on 2013 Financial Results
and
Presentation at Cowen Health Care Conference

San Diego, California and Sydney, Australia (Monday 24 February 2014, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) will hold a conference call to discuss the Company's financial results through December 31, 2013, and its business outlook, including an update on the status of its clinical trials, the development of its next generation technologies, and its ongoing financing efforts. Robert Stockman, the Company’s Chairman and Chief Executive Officer, will host the call.

The call is scheduled for 9:00 a.m. AEDT on Friday, 28 February 2014 (which is 2:00 p.m. US PST on Thursday, February 27, 2014) and may be accessed within Australia by dialing (02) 8223 9773 five minutes prior to the scheduled start time. Callers in the United States and Canada may access the call by dialing 1-877-312-5413. If you are asked to provide an access code, please spell out the word “REVA” to the operator and you will be connected promptly.

If you reside outside of Australia, the United States, or Canada, or if you prefer to access the audiocast through our website, please visit “Events & Presentations” under the “Investors” section of our website at www.revamedical.com, and click on the “listen to webcast” link. A replay of the audiocast will be available on our website after the call.

Mr. Stockman is also scheduled to present at the Cowen and Company 34th Annual Health Care Conference at 2:10 p.m. US EST on Monday, March 3, 2014. The conference is being held March 3rd through 5th at the Boston Marriott Copley Place in Boston, Massachusetts. A copy of the presentation materials will be available in the Investor Relations section of REVA’s website at www.revamedical.com on the day of the presentation.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. The *ReZolve*[®] product family, which is in a clinical study phase, combines REVA’s proprietary stent design with a proprietary polymer that

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com
AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000 • +61 2 9231 3322 • +61 9229 2727 (FAX) • ARBN 146 505 777
REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability.

is metabolized and cleared from the body. REVA's anticipated initial commercial product, the *ReZolve2* scaffold, is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the *ReZolve2* scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the *ReZolve2* scaffold or any of its future products.

United States

Investor and Media Enquiries:

Cheryl Liberatore
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858 966-3045

Australia

Investor Enquiries:

Kim Jacobs
Inteq Limited
+61 2 9229 2700

Media Enquiries:

Rebecca Wilson
Buchan Consulting
+61 3 9866 4722